D. Boral Capital Reaffirms Buy Rating on CERo Therapeutics Holdings, Keeps $30 Price Target

Written by Emily J. Thompson, Senior Investment Analyst

CERO%

Source: Benzinga

Updated: Sep 09 2025

0mins

Source: Benzinga

Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

D. Boral Capital Reaffirms Buy Rating on CERo Therapeutics Holdings, Keeps $30 Price Target

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Faruqi & Faruqi Encourages Gauzy Investors to Discuss Claims

Faruqi & Faruqi Investigates Alexandria Real Estate Equities for Securities Fraud After 19% Stock Drop

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch